Related Experiment Videos
New methods for detection of bladder cancer
1Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
Seminars in Urologic Oncology
|March 21, 1998
Summary
New bladder cancer markers aid detection and surveillance. While not perfect, these biomarkers improve early diagnosis and reduce the need for frequent cystoscopies in superficial bladder cancer management.
Area of Science:
- Urology
- Oncology
- Biomarker Research
Background:
- Superficial bladder cancer frequently recurs but rarely progresses.
- Cystoscopy and urine cytology are standard for bladder cancer detection.
- New biomarkers are emerging for clinical evaluation.
Purpose of the Study:
- To evaluate the role of novel biomarkers in bladder cancer detection.
- To assess the utility of markers in managing superficial bladder cancer recurrence and progression.
- To understand the performance characteristics of available bladder cancer detection assays.
Main Methods:
- Review of current literature on bladder cancer detection markers.
- Analysis of approved and emerging biomarkers such as BTA series, NMP22, and FDP.
- Evaluation of marker performance based on sensitivity and specificity.
Main Results:
- Several new markers (BTA series, NMP22, FDP) are approved for clinical use.
- Markers assist in detecting occult bladder cancer and extending cystoscopy intervals.
- No single marker or combination achieves 100% sensitivity and specificity.
Conclusions:
- Marker selection depends on the clinical objective (detection vs. surveillance).
- Performance characteristics (sensitivity, specificity) guide marker choice.
- Biomarkers enhance bladder cancer management but do not replace cystoscopy entirely.